“ Moderna said Friday that approval of its RSV vaccine was based on clinical trial data showing that even about four months after someone gets the shot, the vaccine had an 83.7% efficacy at preventing lower respiratory tract disease. The vaccine trials involved 37,000 adults in 22 countries.
Moderna says a longer-term analysis showed that the vaccine provided continued protection nearly nine months after vaccination. The company said there were no serious safety concerns identified in the trial, and the most common problems were pain at the injection site, headache and fatigue.”
http://www.cnn.com/2024/05/31/health/moderna-rsv-vaccine-fda-approval/index.html
MRNA is the big future in medicine.
| 